|
Malignant neoplasm of lung
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Additionally, SNP rs9912300 in ACLY gene was significantly associated with overall survival in lung cancer patients (HR, 1.41; 95%CI, 1.02-1.94, p=0.04) under the dominant model.
|
25227797 |
2014 |
|
Malignant neoplasm of lung
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
These findings provide unequivocal proofs that miR-22 is responsible for the posttranscriptional regulation of ACLY, which yields promising therapeutic effects in osteosarcoma, prostate, cervical and lung cancers.
|
27317765 |
2016 |
|
Malignant neoplasm of lung
|
0.050 |
Biomarker
|
disease |
BEFREE |
Importantly, 3K acetylation of ACLY is increased in human lung cancers.
|
23932781 |
2013 |
|
Malignant neoplasm of lung
|
0.050 |
Biomarker
|
disease |
BEFREE |
Finally, to show the therapeutic potential and mechanism of ACLY inhibition for lung cancer treatment, we assessed the effect of RNA interference targeting ACLY on lipogenesis and cell proliferation in A549 cells.
|
18922930 |
2008 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
A lipid-regulating compound, bempedoic acid, was discovered to potently inhibit ACLY, and in animal models, it prevents dyslipidemia and attenuates atherosclerosis.
|
28059952 |
2017 |
|
Arteriosclerosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in <i>Ldlr<sup>-/-</sup></i> Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.
|
28153881 |
2017 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
It must be pointed out that long-term large-scale clinical trials in high-risk patients, are warranted to validate whether ACLY represent a promising therapeutic target for pharmaceutic intervention of dyslipidemia and atherosclerosis; and assess the safety and efficacy profile of ACLY inhibitors in improving cardiovascular outcome of patients.
|
31499095 |
2020 |
|
Arteriosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The LDL-C-lowering and attenuated atherosclerosis in animal models and reduced LDL-C in hypercholesterolemic patients has validated ACLY inhibition as a therapeutic strategy.
|
30586346 |
2019 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
The LDL-C-lowering and attenuated atherosclerosis in animal models and reduced LDL-C in hypercholesterolemic patients has validated ACLY inhibition as a therapeutic strategy.
|
30586346 |
2019 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
A lipid-regulating compound, bempedoic acid, was discovered to potently inhibit ACLY, and in animal models, it prevents dyslipidemia and attenuates atherosclerosis.
|
28059952 |
2017 |
|
Atherosclerosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
It must be pointed out that long-term large-scale clinical trials in high-risk patients, are warranted to validate whether ACLY represent a promising therapeutic target for pharmaceutic intervention of dyslipidemia and atherosclerosis; and assess the safety and efficacy profile of ACLY inhibitors in improving cardiovascular outcome of patients.
|
31499095 |
2020 |
|
Atherosclerosis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in <i>Ldlr<sup>-/-</sup></i> Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid.
|
28153881 |
2017 |
|
Osteoarthritis, Knee
|
0.040 |
Biomarker
|
disease |
BEFREE |
The radiographic knee OA over minimal ten years after ACL reconstruction was systematically reviewed.
|
31404935 |
2019 |
|
Osteoarthritis, Knee
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Twenty studies were eligible, including ACL reconstruction (n=3), knee osteoarthritis (n=3), older adults at risk of sarcopenia (n=13) and patients with sporadic inclusion body myositis (n=1).
|
28259850 |
2017 |
|
Osteoarthritis, Knee
|
0.040 |
Biomarker
|
disease |
BEFREE |
To examine the associations between return to pivoting sport following ACL reconstruction (ACLR) and knee osteoarthritis (OA), and self-reported knee symptoms, function and quality of life after 15 years.
|
29550753 |
2018 |
|
Osteoarthritis, Knee
|
0.040 |
Biomarker
|
disease |
BEFREE |
We compared long-term follow-up from surgical versus non-surgical treatment of ACL rupture regarding radiographic knee osteoarthritis (OA), secondary surgery, laxity and patient-reported outcome measures (PROMs).
|
31732650 |
2019 |
|
Fatty Liver
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Additionally, hepatic SIRT2 overexpression decreased ACLY-3K acetylation and its protein level and alleviated hepatic steatosis in HF/HS diet-fed mice.
|
31197036 |
2019 |
|
Fatty Liver
|
0.030 |
Biomarker
|
disease |
BEFREE |
ACLY is also a target against dyslipidaemia and hepatic steatosis, with a compound currently in phase 3 clinical trials<sup>4,5</sup>.
|
30944472 |
2019 |
|
Fatty Liver
|
0.030 |
Biomarker
|
disease |
BEFREE |
Metabolic pathways are built to elucidate the mechanisms by which VIRG host's higher energy requirements were met: including gene up-regulations for intestinal gluconeogenesis (PEPCK) and liver glycolysis (ENO2), and intriguingly liver fatty acid synthesis through ATP citrate synthase (CS) down-regulation and ATP citrate lyase (ACLY) and malic enzyme (ME) up-regulations.
|
22272335 |
2012 |
|
Non-alcoholic Fatty Liver Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
LncRNA Ttc39aos1 and Acly, may be crucial biomarkers for NAFLD.
|
30466110 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
NAFLD-specific expression and methylation differences were seen for nine genes coding for key enzymes in intermediate metabolism (including PC, ACLY, and PLCG1) and insulin/insulin-like signaling (including IGF1, IGFBP2, and PRKCE) and replicated by bisulfite pyrosequening (independent n = 39).
|
23931760 |
2013 |
|
Non-alcoholic Fatty Liver Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Of note, the livers of mice and humans with NAFLD had increased ACLY protein and ACLY-3K acetylation levels and decreased SIRT2 protein levels.
|
31197036 |
2019 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
To better understand the biologic and molecular basis of distinction between cribriform HGPIN and IDC, we used break-apart fluorescence in-situ hybridization assay to assess ETS gene aberrations, a specific and commonest molecular alteration involving PCa, in a cohort of 16 isolated ACL, presumed to be an isolated cribriform HGPIN, and 45 carcinoma-associated ACL (ACL-PCa) on radical prostatectomy specimens, presumed to be spectrum of IDC-P.
|
20220513 |
2010 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The link between prostate cancer (PC) development and lipid metabolism is well established, with AR intimately involved in a number of lipogenic processes involving SREBP1, PPARG, FASN, ACC, ACLY and SCD1.
|
29466694 |
2018 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The results demonstrated that GOLM1 and ACLY expression was significantly upregulated (P<0.05) in PCa compared with that in normal tissues.
|
31579071 |
2019 |